PEAK6 Investments’s United Therapeutics UTHR Stock Holding History

PEAK6 Investments’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-3	Closed	-$651	–	4615
2023 Q2	$651	Sell	3 -2,531	-100%	-$561K	﹤0.01%	3803
2023 Q1	$567K	Buy	2,534 +2,531	+84,367%	+$624K	﹤0.01%	2288
2022 Q4	$705	Hold	3	–	–	﹤0.01%	4268
2022 Q3	$1K	Hold	3	–	–	﹤0.01%	4798
2022 Q2	$651	Sell	3 -152	-98%	-$30.9K	﹤0.01%	3804
2022 Q1	$28K	Buy	+155	New	+$29.5K	﹤0.01%	4683
2020 Q3	–	Sell	-5,269	Closed	-$578K	–	4919
2020 Q2	$638K	Buy	+5,269	New	+$593K	﹤0.01%	2473
2020 Q1	–	Sell	-17,534	Closed	-$1.67M	–	4580
2019 Q4	$1.54M	Sell	17,534 -67,005	-79%	-$5.9M	0.01%	1270
2019 Q3	$6.74M	Sell	84,539 -59,312	-41%	-$4.78M	0.04%	529
2019 Q2	$11.2M	Buy	143,851 +133,806	+1,332%	+$12.5M	0.07%	318
2019 Q1	$1.18M	Buy	+10,045	New	+$1.17M	0.01%	1718

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

PEAK6 Investments's UTHR Position: Q3 2023 in Review

PEAK6 Investments sold out of United Therapeutics (UTHR) in Q3 2023, closing a stake of 3 shares — an estimated $651 sold.

PEAK6 Investments first reported a position in UTHR in Q1 2019 and held it in 11 quarters. The position peaked at $11.2M in Q2 2019. 508 funds tracked by Wall St. Rank hold UTHR as of Q3 2023.

PEAK6 Investments reported no remaining United Therapeutics position as of Q3 2023 after selling out during the quarter.
PEAK6 Investments sold 3 United Therapeutics shares in Q3 2023, an estimated $651.
PEAK6 Investments first reported a position in United Therapeutics in Q1 2019 and held it in 11 quarters.
PEAK6 Investments's United Therapeutics position peaked at $11.2M in Q2 2019.
508 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2023.

Based on PEAK6 Investments's 13F filing for Q3 2023, filed 13 Nov 2023.